CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tripartite Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tripartite Therapeutics Inc
5F, No.88, Ruihu Street, Neihu District
Phone: +886 227902895p:+886 227902895 TAIPEI, 114  Taiwan Ticker: 79207920
Business Summary
Tripartite Therapeutics Inc is a Taiwan-based company mainly engaged in the development of hydrophilic platform technologies for antibody drug conjugate (ADC) and new drug research and development. It provides ADC design services and subsequent licensing through OmniLink linker technology and Polarpeutic hydrophilic payload modification technology. Its main product is the antibody polar drug conjugate (APDC) developed using the patented OmniLink technology. This APDC consists of the cytotoxic maytansinoid drug conjugated to the trastuzumab antibody. It is used for the drug treatment of various solid tumors such as breast cancer, lung cancer, and gastric cancer. It primarily provides products and services in Taiwan.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025-----

Industries
SIC Code Description
8731 Commercial physical and biological research

General Information
Outstanding Shares: 100 (As of 12/31/2025)
Stock Exchange: TPO
Fax Number: +886 225015698


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, May 16, 2026